Wedbush Maintains Outperform on Pyxis Oncology, Lowers Price Target to $7

Benzinga · 2d ago
Wedbush analyst Robert Driscoll maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and lowers the price target from $8 to $7.